| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
[1,1'-Biphenyl]-4,4'-dicarboxamide,N4,N4'-bis[3-(4,5-dihydro-1H-imidazol-2-yl)phenyl]-, hydrochloride (1:2) manufacturers
- BPH-1358
-
- $30.00
-
2026-07-15
- CAS:5352-53-4
- Purity: 99.74%
- Supply Ability: 10g
- BPH-1358
-
- $30.00
-
2026-07-15
- CAS:5352-53-4
- Purity: 99.74%
- Supply Ability: 10g
|
| | [1,1'-Biphenyl]-4,4'-dicarboxamide,N4,N4'-bis[3-(4,5-dihydro-1H-imidazol-2-yl)phenyl]-, hydrochloride (1:2) Basic information |
| Product Name: | [1,1'-Biphenyl]-4,4'-dicarboxamide,N4,N4'-bis[3-(4,5-dihydro-1H-imidazol-2-yl)phenyl]-, hydrochloride (1:2) | | Synonyms: | [1,1'-Biphenyl]-4,4'-dicarboxamide,N4,N4'-bis[3-(4,5-dihydro-1H-imidazol-2-yl)phenyl]-, hydrochloride (1:2);BPH-1358;Bacterial,inhibit,Inhibitor,NSC 50460,NSC-50460,BPH-1358,BPH 1358,BPH1358;N4,N4'-bis(3-(4,5-dihydro-1H-imidazol-2-yl)phenyl)-[1,1'-biphenyl]-4,4'-dicarboxamide dihydrochloride;BPH-1358 HCl | | CAS: | 5352-53-4 | | MF: | C32H29ClN6O2 | | MW: | 565.07 | | EINECS: | | | Product Categories: | | | Mol File: | 5352-53-4.mol | ![[1,1'-Biphenyl]-4,4'-dicarboxamide,N4,N4'-bis[3-(4,5-dihydro-1H-imidazol-2-yl)phenyl]-, hydrochloride (1:2) Structure](CAS/20211123/GIF/5352-53-4.gif) |
| | [1,1'-Biphenyl]-4,4'-dicarboxamide,N4,N4'-bis[3-(4,5-dihydro-1H-imidazol-2-yl)phenyl]-, hydrochloride (1:2) Chemical Properties |
| Melting point | 330 °C | | storage temp. | -20°C | | solubility | DMF: insol,DMSO: 1 mg/ml,Ethanol: insol,PBS (pH 7.2): insol | | form | A solid | | color | White to off-white |
| | [1,1'-Biphenyl]-4,4'-dicarboxamide,N4,N4'-bis[3-(4,5-dihydro-1H-imidazol-2-yl)phenyl]-, hydrochloride (1:2) Usage And Synthesis |
| Uses | BPH-1358 (NSC50460) is a potent human farnesyl diphosphate synthase (FPPS) and undecaprenyl diphosphate synthase (UPPS) inhibitor with IC50s of 1.8 μM and 110 nM, respectively, and is active against S. aureus in vitro (MIC ~250 ng/mL)[1][2]. | | in vivo | BPH-1358 is active against S. aureus in vivo (20/20 mice survived in an i.p. infection model with a MRSA strain)[1]. | | References | [1] Zhu W, et al. Antibacterial drug leads: DNA and enzyme multitargeting. J Med Chem. 2015 Feb 12;58(3):1215-27. DOI:10.1021/jm501449u [2] Liu YL, et al. Farnesyl diphosphate synthase inhibitors with unique ligand-binding geometries. ACS Med Chem Lett. 2015 Jan 29;6(3):349-54. DOI:10.1021/ml500528x |
| | [1,1'-Biphenyl]-4,4'-dicarboxamide,N4,N4'-bis[3-(4,5-dihydro-1H-imidazol-2-yl)phenyl]-, hydrochloride (1:2) Preparation Products And Raw materials |
|